• AdaptDx dark adaptation testing selected for large AMD study

    One year ago - By Healio

    MacuLogix Inc. announced that AdaptDx has been selected as a functional testing device for candidate clinical endpoint development in the MACUSTAR project, a 5-year study exploring novel outcome measures for future interventional trials in patients with intermediate age-related macular degeneration.
    The investigation is currently funded with more than 16 million euros from the European Innovative Medicines Initiative and will enroll 750 patients in seven countries across Europe, according to a press release from MacuLogix.
    AdaptDx, the only commercially available automated dark adaptometer,
    Read more ...